
To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). This phase 1, double‐blind, placebo‐controlled, parallel‐dose, multiple‐ascending dose study randomized participants to once weekly subcutaneous tirzepatide or placebo. The tirzepatide treatment groups were: 5 mg (5 mg weeks 1‐8), 10 mg (2.5 mg weeks 1‐2; 5 mg weeks 3‐4; 10 mg weeks 5‐8), and 15 mg (5 mg weeks 1‐2; 10 mg weeks 3‐6; 15 mg weeks 7‐8). The primary outcome was tirzepatide safety and tolerability...
Like
Save
Share